Author

R. B. Corcoran

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Research Focus:differential expression· 1 Approach:experimental assay· 1 Assay:proteomics· 1 Approach:statistical model· 1 Research Focus:variant calling· 1 Assay:whole-exome sequencing· 1

Frequent Co-Authors

A. M. Egloff· 1 shared A. M. Wolff· 1 shared A. R. Parikh· 1 shared B. C. Bastian· 1 shared B. D. Miller· 1 shared B. E. Johnson· 1 shared B. L. Norden· 1 shared B. Nadres· 1 shared

Activity by Year

2019-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. M. Egloff

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Ultrasensitive detection of circulating LINE-1 ORF1p as a specific multi-cancer biomarker

M. S. Taylor, W. Connie, P. C. Fridy, S. J. Zhang, Y. Senussi, J. C. Wolters, W.-C. Cheng, J. Heaps, B. D. Miller, K. Mori, L. Cohen, H. Jiang, K. R. Molloy, B. L. Norden, B. T. Chait, , O. H. Yilmaz

This study develops ultrasensitive assays to detect ORF1p in plasma, showing its potential as a multi-cancer biomarker for early detection and monitoring.

bioRxiv · Jan 25, 2023 · PreprintCancer Biology

Co-occurring alterations in the RAS-MAPK pathway limit response to MET inhibitor treatment in MET exon 14 skipping mutation positive lung cancer

J. K. Rotow, P. Gui, W. Wu, V. M. Raymond, R. B. Lanman, F. J. Kaye, N. Peled, F. Fece de la Cruz, B. Nadres, R. B. Corcoran, I. Yeh, B. C. Bastian, P. Starostik, K. Newsom, V. R. Olivas, , C. M. Blakely

The paper identifies co-occurring RAS-MAPK pathway alterations in MET exon 14 skipping mutation positive lung cancers that limit response to MET inhibitors and suggests combining MET and MEK inhibitors to overcome resistance.

bioRxiv · May 24, 2019Cancer Biology